...
首页> 外文期刊>Breast Cancer: Basic and Clinical Research >Quality of Life and Neutropenia in Patients with Early Stage Breast Cancer: A Randomized Pilot Study Comparing Additional Treatment with Mistletoe Extract to Chemotherapy Alone
【24h】

Quality of Life and Neutropenia in Patients with Early Stage Breast Cancer: A Randomized Pilot Study Comparing Additional Treatment with Mistletoe Extract to Chemotherapy Alone

机译:早期乳腺癌患者的生活质量和中性粒细胞减少症:一项随机试验研究,比较了槲寄生提取物与单独化疗的额外治疗

获取原文
           

摘要

Background: Chemotherapy for breast cancer often deteriorates quality of life, augments fatigue, and induces neutropenia. Mistletoe preparations are frequently used by cancer patients in Central Europe. Physicians have reported better quality of life in breast cancer patients additionally treated with mistletoe preparations during chemotherapy. Mistletoe preparations also have immunostimulant properties and might therefore have protective effects against chemotherapy-induced neutropenia.Patients and Methods: We conducted a prospective randomized open label pilot study with 95 patients randomized into three groups. Two groups received Iscador? M special (IMS) or a different mistletoe preparation, respectively, additionally to chemotherapy with six cycles of cyclophosphamide, adriamycin, and 5-fluoro-uracil (CAF). A control group received CAF with no additional therapy. Here we report the comparison IMS (n = 30) vs. control (n = 31). Quality of life including fatigue was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30). Neutropenia was defined as neutrophil counts <1,000/μl and assessed at baseline and one day before each CAF cycle.Results: In the descriptive analysis all 15 scores of the EORTC-QLQ-C30 showed better quality of life in the IMS group compared to the control group. In 12 scores the differences were significant (p < 0.02) and nine scores showed a clinically relevant and significant difference of at least 5 points. Neutropenia occurred in 3/30 IMS patients and in 8/31 control patients (p = 0.182).Conclusions: This pilot study showed an improvement of quality of life by treating breast cancer patients with IMS additionally to CAF. CAF-induced neutropenia showed a trend to lower frequency in the IMS group.
机译:背景:乳腺癌的化学疗法通常会降低生活质量,加剧疲劳并诱发中性粒细胞减少。槲寄生制剂在中欧的癌症患者中经常使用。医师报告说,在化疗期间额外接受槲寄生制剂治疗的乳腺癌患者的生活质量更高。槲寄生制剂还具有免疫刺激特性,因此可能对化疗诱导的中性粒细胞减少症具有保护作用。两组收到Iscador?除了六个周期的环磷酰胺,阿霉素和5-氟尿嘧啶(CAF)的化学疗法外,分别使用特殊药物(IMS)或不同的槲寄生制剂。对照组接受了CAF,没有额外的治疗方法。在这里,我们报告了IMS(n = 30)与对照(n = 31)的比较。包括疲劳在内的生活质量已通过欧洲研究与治疗癌症生活质量调查表(EORTC-QLQ-C30)进行了评估。中性粒细胞减少症的定义为中性粒细胞计数<1,000 /μl,并在每个CAF周期的基线和前一天进行评估。控制组。在12个评分中,差异具有显着性(p <0.02),而在9个评分中,临床相关且显着性差异至少为5分。中性粒细胞减少症发生在3/30 IMS患者和8/31对照患者中(p = 0.182)。结论:这项初步研究显示,通过在CAF之外使用IMS治疗乳腺癌患者可以改善生活质量。 CAF诱导的中性粒细胞减少症在IMS组中呈降低频率的趋势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号